Although radioimmunotherapy (RIT)appears to have promise as a new therapeutic modality for lymphoma, suboptimal delivery of radiation to tumor sites and dose-limiting myelosuppression remain as significant problems. The guiding hypothesis of this project is that RIT of B-cell lymphoma can be further enhanced a) through the use of radiolabeled monoclonal antibodies with more restricted specificity for Bcells than those previously used, b) through the manipulation of antibodydosing methods, and c) through the use of a bone marrow radioprotective cytokine such as interleukin-1-alpha (IL-1-alpha). To study theseinterrelated issues the applicant will perform a stepwise, three-part phaseI clinical trial. In Part I, the maximum tolerated dose (MTD) of 131-I-anti-B1 which does not require bone marrow transplantation support and is suitablefor a multiple dosing schedule will be determined by phase I radiation dose-escalation in successive groups of patients. As part of the assessment of toxicity, detailed studies regarding peripheral blood and bone marrow hematopoetic recovery (including bone marrow progenitor assays) will be performed. Also, in this part of the trial the issue of tumor targeting will be addressed in a study in which the effects of varying levels of unlabeled antibody predosing on the biodistribution of trace-labeled anti-B1 will be determined. The results from these tracer studies will be applied to the planningof the subsequent delivery of an RIT dose in each patient. In Part II, the feasibility, safety, and toxicity of combining IL-1-alpha with 131-I-anti-B1 will be determined in patients entered onto three successive escalating dose levels of IL-1-alpha given before the MTD of 131-I-anti-B1 determined in Part I. The same detailed hematologic studies will be performed in thesepatients who have received IL-1-alpha so that they may be compared to the patients not given IL-1-alpha in Part I. In part III, it will be determined whether a higher MTD of 131-I-anti-B1 can be given to patients who have received a pretreatment with IL-1-alpha. Detailed hematologic studies will continue to be performed for further comparative purposes.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Kaminski, Mark S; Tuck, Melissa; Estes, Judith et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-9
Koral, Kenneth F; Dewaraja, Yuni; Li, Jia et al. (2003) Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med 44:457-64
Koral, Kenneth F; Francis, Isaac R; Kroll, Stewart et al. (2002) Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. Cancer 94:1258-63
Nordoy, T; Kolstad, A; Tuck, M K et al. (2001) Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 100:40-8
Koral, K F; Dewaraja, Y; Clarke, L A et al. (2000) Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm 15:347-55
Koral, K F; Dewaraja, Y; Li, J et al. (2000) Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma. J Nucl Med 41:1579-86
Kaminski, M S; Estes, J; Zasadny, K R et al. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-66
Koral, K F; Li, J; Dewaraja, Y et al. (1999) I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images. Clin Cancer Res 5:3004s-3009s
Wahl, R L (1998) Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J Nucl Med 39:1S
Wahl, R L; Zasadny, K R; MacFarlane, D et al. (1998) Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 39:21S-27S

Showing the most recent 10 out of 18 publications